Johnson & Johnson Enters US Robotic Surgery Market with Ottava System

Johnson & Johnson has secured FDA marketing authorization for its Ottava robotic surgical system, paving the way for the company to enter the lucrative US market for robotic-assisted surgery. The healthcare giant’s entry into this space marks a significant challenge to Intuitive Surgical’s dominance with its da Vinci system.

Ottava’s smaller footprint and integrated design may give it an edge over more cumbersome systems. According to Hani Abouhalka, chairman of surgery at J&J MedTech, “Our intention is to lead in surgical robotics.” With Ottava approved for several general surgery procedures, including gastric bypass and gallbladder removal, the company appears committed to gaining market share.

However, analysts remain skeptical about J&J’s ability to challenge da Vinci’s stranglehold on the robotic-assisted surgery market. JP Morgan’s Robbie Marcus notes that while Ottava has some interesting features, “our doc checks continue to point to Intuitive as the clear favorite given its physician relationships and entrenched integration into hospital workflow and academic programs.”

The entry of J&J into the robotic surgery market raises questions about what this means for patients. Will Ottava’s smaller footprint make it more accessible to hospitals in resource-constrained areas? And how will its adoption impact the way surgeons work?

Increased competition could drive innovation, but there is also a risk of fragmentation: if too many companies are chasing this space, it could lead to confusion among hospitals and patients, ultimately diluting the benefits of robotic-assisted surgery.

As J&J seeks approval for additional procedures and expands into new markets, analysts will be watching closely. The company must build relationships with physicians, hospitals, and other stakeholders while balancing innovation against disrupting established workflows. Abouhalka’s statement “Our intention is to lead in surgical robotics” remains a promise yet to be fulfilled.

The entry of J&J into the robotic-assisted surgery market is about to make this space more competitive. With Ottava now on the scene, one question will dominate the conversation: can anyone truly challenge da Vinci’s dominance?